XSHE
003017
Market cap278mUSD
Jul 10, Last price
22.35CNY
1D
-0.62%
1Q
-28.48%
IPO
-51.08%
Name
Zhejiang Dayang Biotech Group Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Dayang Biology Technology Co.,Ltd. is a diversified enterprise specializing in the research, development, manufacturing, and global distribution of biological products, agricultural chemicals, and a broad spectrum of chemical compounds. Its extensive product portfolio includes a range of fundamental inorganic chemicals such as potassium carbonate (available in both general and food additive grades) and potassium bicarbonate (also offered as a food additive). They also supply ammonium chloride, catering to both agricultural and industrial needs. Beyond these, the company produces more specialized chemical derivatives, including 2-chloro-6-fluorobenzaldehyde, 2-chloro-6-fluorobenzyl chloride, and various anisole-based products. Furthermore, Zhejiang Dayang is a supplier of veterinary active pharmaceutical ingredients (APIs), exemplified by amprolium HCL, and manufactures veterinary drug premixes, such as enramycin premixes. Established in 1976, the company maintains its headquarters in Jiande, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑00 | 2018‑12 | 2017‑12 | 2017‑00 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||